Navigation Links
CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices
Date:12/1/2009

NEWNAN, Ga., Dec. 1 /PRNewswire/ -- CeloNova BioSciences, Inc., a provider of specialty surface treatments for medical devices and of specialty implants, today announced that President and Chief Executive Officer, Thomas A. Gordy, will give an opening address for the Technology Parade at the Innovations in Cardiovascular Interventions Conference in Tel Aviv, Israel. "We must leave the era of petty self-interest behind and focus the rich intellectual resources of the health care industry toward collaboration, innovation, and rapid market entry. We need more heart, more passion, and more integrity. With laser-like focus, we can truly heal the world," said Gordy. "The international faculty at ICI is renowned for spotlighting transformative technology."

(Logo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080LOGO-b)

(Photo: http://www.newscom.com/cgi-bin/prnh/20081007/CLTU035-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20081001/CLW080-c)

About CeloNova BioSciences: Headquartered in Newnan, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices that are enhanced by one of the Company's proprietary materials, Polyzene®-F, a lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant surface treatment for implanted medical devices. The Company's current products include Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene®-F. Both products are CE Marked. Embozene(TM) Microspheres have been approved by the FDA for the treatment of hypervascularized tumors and arteriovenous malformations. For more information, please visit www.celonova.com

About Innovations in Cardiovascular Interventions: The ICI meeting for interventional cardiologists, innovators, and industry will be held December 6-8, in Tel-Aviv, Israel. It is a continuation of the series of interventional cardiology conferences held in Israel since 1995. The upcoming meeting will focus on innovative technology, therapies, and research at various levels of development, with thematic live case presentations to present the impact of these technologies on current and future therapy.


Contact: Theresa Wilson  (770) 502-0304; (678) 895-6486

SOURCE CeloNova BioSciences, Inc.


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
2. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
3. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
4. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
5. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
7. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
8. Cell Biosciences Completes Acquisition of Alpha Innotech
9. Neurocrine Biosciences Reports Third Quarter 2009 Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... Plastics, has added Kybella® to his medical and surgical expertise. Technically known as ... FDA injectable medication used as a non-surgical alternative for reduction of fat below ...
(Date:2/6/2016)... San Rafael, CA (PRWEB) , ... February 06, 2016 , ... ... 2016 Youth Ultimate Coaching Conference (YUCC) . This event brings together top non-profit leaders, ... is “Gender Equity and Girls Ultimate”. Valerio Iani, Bay Area Disc Program Director of ...
(Date:2/6/2016)... ... 06, 2016 , ... Shark Finds and Kevin Harrington, along with ... DRTV campaign with Belly Bands. , Having a dog is great—except when it wets ... and find nothing works, get Belly Bands, the easiest way to stop dogs ...
Breaking Medicine News(10 mins):